ESR1 and breast cancer: Neoadjuvant chemotherapy (NAC) is an increasingly used therapeutic option, particularly in younger women with locally advanced, high-grade, estrogen-receptor-negative (ER-) breast cancer (BC) and more advanced nodal disease [1,2].